Formulary guidance and transparency from P&T to point of care


Reality Check on Duchenne Muscular Dystrophy

Market access for Duchenne muscular dystrophy treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, about 35% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In February 2021, the FDA gave accelerated approval to Sarepta Therapeutics, Inc.’s Amondys 45 (casimersen) for the treatment of Duchenne muscular dystrophy in people with a confirmed mutation amenable to exon 45 skipping
  • Key Findings: There are multiple products in Phase III or later of clinical trials. Treatments in the development pipeline include therapeutic approaches that restore or replace dystrophin and those that treat Duchenne symptoms, such as those that protect muscles by reducing fibrosis and inflammation

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.